Similarly, sorafenib and lenvatinib have been demonstrated to suppress EMT by inhibiting the phosphorylation of Akt and ERK, suggesting their potential in preventing HCC progression after iRFA.146, 147. This evidence concerns the gene AKT1 and hepatocellular carcinoma.